Chapter 45 Iggy Interventions for clients with problems of the CNS
Shared by: HC120730003454
-
Stats
- views:
- 6
- posted:
- 7/29/2012
- language:
- pages:
- 11
Document Sample


Chapter 45
Interventions for Clients with Problems of the Central
Nervous System: The Brain
Headaches
• Migraine headache
• Episodic familial disorder manifested by unilateral,
frontotemporal, throbbing pain in the head, often worse behind
one eye or ear
• Often accompanied by a sensitive scalp, anorexia, photophobia,
nausea
• Aura: sensation that signals the onset of a headache or seizure
Drug Therapy
• Abortive therapy: alleviating pain during the early aura phase
includes prescribing ergotamine derivatives, NSAIDs, triptans,
isometheptene combinations.
• Acetaminophen and NSAIDs are usually effective for mild
migraine headaches.
Preventive Therapy
• NSAID prescription
• Beta-adrenergic blocker
• Calcium channel blockers
Complementary and Alternative Therapies
• Yoga, meditation, massage, exercise, biofeedback, relaxation
techniques
• Acupuncture
• Use of herbs and nutritional therapies with approval
• Avoidance of trigger events that may result in migraine episodes,
such as tension and stress
Cluster Headache
• Histamine cephalagia, uncommon type of headache
• Cause unknown; attributed to vasoreactivity and oxyhemoglobin
desaturation
• Unilateral, radiating to forehead, temple, or cheek
• Ipsilateral tearing of the eye, rhinorrhea, ptosis, and miosis
Therapy
• Same types of drugs used for migraines
• Client to wear sunglasses and avoid sunlight
• Oxygen via mask
• Avoidance of precipitating factors, such as anger, excitement
• Surgical management
Tension Headache
• Neck and shoulder muscle tenderness and bilateral pain at the
base of the skull and in the forehead
• Head pain without associated symptoms
• Treatment: non-opioid analgesics, muscle relaxants, occasional
opioids
• Ibuprofen plus caffeine
• Prophylactic treatment similar to that used in treating migraine
headaches
Seizures and Epilepsy
• Seizure: abnormal, sudden, excessive, uncontrolled electrical
discharge of neurons within the brain; may result in alteration in
consciousness, motor or sensory ability, and/or behavior
• Epilepsy: chronic disorder with recurrent, unprovoked seizures;
may be caused by abnormality in electrical neuronal activity,
and/or imbalance of neurotransmitters (such as GABA)
Types of Seizures
• Generalized seizures
• Partial seizures
• Unclassified seizures
Types of Epilepsy
• Primary or idiopathic epilepsy: not associated with any
identifiable brain lesion
• Secondary epilepsy: results from an underlying brain lesion, most
commonly a tumor or trauma
Seizures Risks
• Seizures may result from:
• Metabolic disorders
• Acute alcohol withdrawal
• Electrolyte disturbances
• Heart disease
Collaborative Management
• A complete description of the type of seizure activity that occurs
and events surrounding the seizure determines the best treatment
plan.
• Determine whether an aura was present before the seizure in the
preictal phase.
• Diagnostic testing is performed.
Drug Therapy
• Evaluate most current blood level of medication, if appropriate.
• Be aware of drug-drug and drug-food interactions.
• Maintain therapeutic blood levels for maximal effectiveness.
(Continued)
Drug Therapy (Continued)
• Do not administer warfarin with phenytoin.
• Document and report side and adverse effects.
Client and Family Education
• Antiepileptic drugs (AEDs) may not be stopped, even if seizures
stop.
• Refer limited-income clients to social services.
• All states prohibit discrimination against people who have
epilepsy.
(Continued)
Client and Family Education (Continued)
• Alternative employment may be needed.
• Vocational rehabilitation may be subsidized.
Seizure Precautions
• Oxygen and suctioning equipment should be readily available.
• Saline lock may be necessary.
• Side rails should be up at all times.
• Padded side rail use is controversial.
• Place bed in lowest position.
• Never insert padded tongue blades into the client’s mouth during
a seizure.
Seizure Management
• If simple partial seizure, observe the client and document the
seizure.
• Turn the client on the side during a generalized tonic-clonic
seizure; if possible, turn the client’s head to prevent aspiration.
• Cyanosis usually is self-limiting.
• Do not restrain.
Status Epilepticus Management
• Usual causes of status epilepticus:
• Prolonged seizures lasting more than 5 minutes or repeated
seizures over the course of 30 minutes
• Neurologic emergency that must be treated promptly and
aggressively
• Sudden withdrawal of AEDs, infections, alcohol withdrawal,
head trauma, cerebral edema, and metabolic disturbances
Status EpilepticusTreatment
• Establish an airway.
• Administer oxygen as indicated.
• Establish intravenous access.
• For continuous monitoring, admit client to intensive care unit.
• Give IV diazepam, lorazepam, phenytoin, fosphenytoin, or general
anesthesia.
(Continued)
Status EpilepticusTreatment (Continued)
• Other treatments include:
• Surgical management: epileptic region in a resectable area
• Corpuscallostomy
• Vagal nerve stimulation
Meningitis
• Meningitis: inflammation of the arachnoid and pia mater of the
brain and spinal cord and the cerebrospinal fluid
• Bacterial and viral origins most common: fungal and protozoal
meningitis
(Continued)
Meningitis (Continued)
• Viral meningitis: self-limiting and client recovers
• Bacterial meningitis: a medical emergency with a mortality rate of
approximately 25%.
Physical Assessment and Clinical
Manifestations
• Signs and symptoms of meningitis: headache, nausea, vomiting,
and fever
• Photophobia and indications of increased intracranial pressure
• Nuchal rigidity and positive Kernig’s and Brudzinski’s signs (only
present in 9% of clients)
• Seizure, decreased mental status, focal neurologic deficits
Laboratory Assessment of Meningitis
• Cerebrospinal fluid analysis
• Computed tomography scan
• Blood cultures
• Counterimmunoelectrophoresis
• Polymerase chain reaction
• Complete blood count
• X-ray study to determine presence of infection
Drug Therapy
• Broad-spectrum antibiotic
• Hyperosmolar agents
• Anticonvulsants
• Steroids (controversial)
• Prophylaxis treatment for those who have been in close contact
with the meningitis-infected client
Encephalitis
• Inflammation of the brain parenchyma and often the meninges;
affects the cerebrum, brainstem, and cerebellum
• Viral cause, most often bacteria, fungi, or parasites
• Degeneration of neurons of the cortex
• Hemorrhage, edema, necrosis, small lacunae develop in cerebral
hemispheres
Interventions
• Prompt recognition and treatment of signs of cerebral edema,
hemorrhage, and necrosis of brain tissue
• Establishment of patent airway
• Assessment of vital signs
• Continuous supportive care and assessment
Parkinson Disease
• Debilitating disease affecting motor ability characterized by
tremor, rigidity, akinesia, and postural instability
• Parkinson disease is separated into stages by degree of disability:
1, 2, 3, 4, and 5.
• Exact cause unknown, possibly involving environmental and
genetic factors
Assessment
• Fatigue, slight tremor, problems with manual dexterity
• Rigidity, changes in facial expression, uncontrolled drooling,
dementia, changes in voluntary movement, excessive perspiration,
orthostatic hypotension
• No specific diagnostic tests
Drug Therapy in Parkinson Disease
• Anticholinergic drugs: amantadine, selegiline (confer mild benefit)
• Dopamine agonists in the first 3 to 5 years
• Levodopa
• Bromocriptine or pergolide
• Amantadine
Drug Toxicity
• Long-term drug therapy regimens often cause delirium, cognitive
impairment, decreased effectiveness of the drug, or hallucinations.
• Reduce medication dose.
• Change medications or frequency of administration.
• Take “drug holiday,” especially in the use of levodopa therapy.
Management of Parkinson Disease
• Exercise and ambulation
• Self-care
• Injury prevention
• Nutrition
• Communication
• Psychosocial support
(Continued)
Management of Parkinson Disease (Continued)
• Surgical management includes:
• Deep brain stimulation
• Fetal tissue transplantation
Alzheimer’s Disease
• Chronic, progressive, degenerative disease that accounts for 60%
of dementias occurring in people older than 65 years of age
• Loss of memory, judgment, and visuospatial perception, and
change in personality
• Increasing cognitive impairment, severe physical deterioration,
death from complications of immobility
Structural Changes in the Brain
• Alzheimer’s disease creates changes that include:
• Neurofibrillary tangles
• Senile or neuritic plaques
• Increased amounts of an abnormal protein, beta amyloid
(Continued)
Structural Changes in the Brain (Continued)
• Significantly increased vascular degeneration a contributor to
mortality in this disorder
• Abnormalities of ACH, norepinephrine, dopamine, and
serotonin
Chemical Changes in the Brain
• Alzheimer’s disease creates changes that include abnormalities in
the neurotransmitters:
• Acetylcholine
• Norepinephrine
• Dopamine
• Serotonin
• Their exact role is not well understood.
Manifestations
• Changes in cognition
• Alterations in communication and language abilities
• Changes in behavior, personality, and judgment
• Changes in self-care skills
• Psychosocial assessment, especially client’s reaction to changes in
routine
Interventions in Alzheimer’s Disease
• Answer client’s questions truthfully.
• Assess and treat other medical problems.
• Provide cognitive restructuring and memory training.
• Structure the environment to increase client’s ability to function.
• Prevent overstimulation.
Interventions
• Provide consistency, orientation, and validation therapy.
• Promote independence in activities of daily living.
• Promote bowel and bladder continence.
(Continued)
Interventions (Continued)
• Assist with facial recognition as the disease progresses to
prosopagnosia, an inability to recognize oneself and other familiar
faces.
• Promote communication with clear, short sentences.
Drug Therapy
• Cholinesterase inhibitors
• Memantine
• Donepezil
• Antidepressants
• Psychotropic drugs
• Complementary and alternative therapies
Risk for Injury
• Interventions for the client with Alzheimer’s disease include:
• Coping with restlessness and wandering; ensuring client wears
identification bracelet; registering client in Safe Return
Program; providing frequent walks and structured activities
(Continued)
Risk for Injury (Continued)
• Ensuring safety by removing all potentially dangerous objects,
particularly in case seizures occur
• Minimizing agitation by talking calmly and softly; displaying
positive affect; making calm movements; offering diversion
Compromised Family Coping
• Interventions for the caregiver role:
• Encourage family to seek legal counsel regarding client’s
competency, need to obtain guardianship, or durable medical
power of attorney, when necessary.
• Make caregivers and family aware of their own health and
stress resulting from new responsibilities for care.
Disturbed Sleep Pattern
• Difficulty sleeping at night with frequent naps in the day
• Interventions for establishing sleep pattern:
• Re-establish the usual day-night pattern by providing activity
and exercise during the day.
• Establish before-bedtime ritual.
(Continued)
Disturbed Sleep Pattern (Continued)
• Adjust treatment and medication schedule to provide for
uninterrupted sleep.
• Give mild antianxiety agent or hypnotic.
Huntington Disease
• Hereditary disorder transmitted as an autosomal dominant trait
at the time of conception
• Gradual clinical onset of progressive mental status changes,
leading to dementia and choreiform movements in the limbs,
trunk, and facial muscles
• Three stages each lasting about 5 years over an average 15 years
of the disease
Management of Huntington Disease
• No known cure or treatment
• Genetic counseling
• Antipsychotic agents or monoamine-depleting agents used to
manage movement abnormalities that are disabling or interfere
with ADLs
• Medications to treat depression, anxiety, and obsessive-compulsive
behaviors
Get documents about "